A feasibility study of bevacizumab plus dose-dense doxorubicin- cyclophosphamide (AC) followed by nanoparticle albumin-bound paclitaxel in early-stage breast cancer Academic Article uri icon

Overview

MeSH Major

  • Antibodies, Monoclonal
  • Antineoplastic Combined Chemotherapy Protocols
  • Breast Neoplasms
  • Carcinoma
  • Cyclophosphamide
  • Doxorubicin
  • Paclitaxel

abstract

  • Bevacizumab with ddAC → nab-paclitaxel had a low rate of cardiac events; cTn and PRA levels are not predictive of CHF or HTN, respectively. The efficacy of bevacizumab as adjuvant treatment will be established in several ongoing phase III trials.

authors

publication date

  • May 15, 2011

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC4994894

Digital Object Identifier (DOI)

  • 10.1158/1078-0432.CCR-10-1969

PubMed ID

  • 21350003

Additional Document Info

start page

  • 3398

end page

  • 407

volume

  • 17

number

  • 10